BTG COMPLETES SALE OF RFID PATENT PORTFOLIO

Main Menu | News By Date | News By Supplier | News By Category | About Us

BTG COMPLETES SALE OF RFID PATENT PORTFOLIO
19 April 2007 - BTG

BTG plc, the medical innovations company, today announces that Zebra Technologies Corporation has exercised its option to acquire the remainder of BTG's radio frequency identification patent portfolio for $3.8 million gross.

An additional $1.4 million is receivable in relation to the sale of these and other RFID patents on satisfaction of certain conditions.

BTG has already received $5.8 million from Zebra relating to this option and the sale of the other RFID patents

Louise Makin, Chief Executive Officer, said: "We are pleased with the sale of our remaining RFID patents to Zebra. This divestment is in line with our strategy to exit and realise value from our non-core technology areas whilst expanding and developing our pipeline of medical products."

As previously announced, BTG also earned $5.0m gross from the sale of its WebNav online tracking patents in the first half of the current financial year. Interim results for the half year ending 30 September 2006 will be published on 9 November 2006, when BTG will also present an update for analysts on its R&D pipeline.

http://www.btgplc.com

About: BTG
BTG is an intellectual property and technology commercialisation company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realise value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialised important innovations, including Magnetic Resonance Imaging, Multilevel Cell Memory, Campath (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukaemia, and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd and BTG International Inc in the UK and USA, respectively.

More News:
  • For April 2007
  • From BTG
  • For Polymer OLED Devices